Every 10-K that Amesite Inc. (AMST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AMST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMST filings page.
Amesite Inc. (AMST) reported fiscal 2026 revenue of $364,777, compared with $110,459 in fiscal 2025. It launched a census-based NurseMagic™ Enterprise tier with electronic medical record compatibility, automated interdisciplinary team reporting and configurable documentation, introduced NurseMagic™ EMR capability, and secured its largest enterprise deployment, serving an approximately 2,700-patient census.
Net loss was $3,095,838, compared with $3,617,086 in fiscal 2025; operating cash used was $2,146,717. The April 2026 registered and private placements generated approximately $2.6 million in gross proceeds. Cash, cash equivalents and restricted cash totaled $2,398,809 as of June 30, 2026. Management said it may not have sufficient cash to maintain planned operations for the next 12 months following issuance of the financial statements. Its plans to generate cash through financing transactions are subject to market conditions and outside the company’s control; management concluded they do not alleviate substantial doubt about Amesite’s ability to continue as a going concern.
Amesite Inc. filed Amendment No. 1 to its Annual Report (10-K/A) to amend and restate Part III (Items 10–14) and the cover page for the year ended June 30, 2025. The update consolidates director, executive, compensation, ownership, related‑party, and auditor fee disclosures into the annual report, and includes Section 302 certifications. The company states no other changes to the original report.
As of October 24, 2025, shares outstanding were 4,572,713. The aggregate market value of common stock held by non‑affiliates on December 31, 2024 was $15,375,000 based on a $4.75 closing price. The board lists five directors, with three independent (Nasdaq criteria). The filing notes several directors each filed one late Form 4 during fiscal 2025. CEO Ann Marie Sastry’s fiscal 2025 salary was $550,000. Under the 2018 Equity Incentive Plan, 371,568 shares remained available for future issuance as of June 30, 2025. Audit and related fees for 2025 totaled $150,262. Beneficial ownership shows Dr. Sastry at 919,181 shares (20.1%).
Amesite Inc. (AMST) reported a net loss of approximately $3,617,000 for the fiscal year ended June 30, 2025 and had stockholders' equity of about $2,739,000 on that date. The company had 4,572,713 shares outstanding at June 30, 2025 versus 2,542,440 a year earlier, reflecting recent equity issuances. Amesite completed a public offering of 1,201,667 shares at $3.00 per share, generating approximately $3.6 million gross and about $3.1 million net proceeds, with direct offering costs of $1,164,050 deducted from equity.
The company recorded a $90,869 impairment of capitalized software after discontinuing a higher ed/professional learning app to focus on its NurseMagic app, and recognized warrants issued in connection with underwriting with a fair value of approximately $95,984. Revenues show customer concentration: one line notes 41% of revenues from a single source and that five customers accounted for 97% of 2024 revenue. Cash, cash equivalents and restricted cash of about $2,433,000 are reported.